drugset / Trial / NCT07218653
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
Phase 0
Not yet recruiting
72 enrolled
University of Wisconsin, Madison
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverTriple-blindBasic science
Summary
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.
Timeline
- Start
- 2026-10
- Primary completion
- 2031-07
- Completion
- 2031-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indomethacin | Small molecule | 1.5 mg/kg | Oral |